159 related articles for article (PubMed ID: 8881815)
1. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.
Löfberg R; Rutgeerts P; Malchow H; Lamers C; Danielsson A; Olaison G; Jewell D; Ostergaard Thomsen O; Lorenz-Meyer H; Goebell H; Hodgson H; Persson T; Seidegård C
Gut; 1996 Jul; 39(1):82-6. PubMed ID: 8881815
[TBL] [Abstract][Full Text] [Related]
2. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
Gastroenterology; 1996 Jan; 110(1):45-51. PubMed ID: 8536887
[TBL] [Abstract][Full Text] [Related]
3. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
[TBL] [Abstract][Full Text] [Related]
4. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
[TBL] [Abstract][Full Text] [Related]
5. A comparison of budesonide with prednisolone for active Crohn's disease.
Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
[TBL] [Abstract][Full Text] [Related]
6. Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.
Ferguson A; Campieri M; Doe W; Persson T; Nygård G
Aliment Pharmacol Ther; 1998 Feb; 12(2):175-83. PubMed ID: 9692692
[TBL] [Abstract][Full Text] [Related]
7. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
[TBL] [Abstract][Full Text] [Related]
8. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.
Gross V; Andus T; Ecker KW; Raedler A; Loeschke K; Plauth M; Rasenack J; Weber A; Gierend M; Ewe K; Schölmerich J
Gut; 1998 Apr; 42(4):493-6. PubMed ID: 9616309
[TBL] [Abstract][Full Text] [Related]
9. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group.
Ewe K; Böttger T; Buhr HJ; Ecker KW; Otto HF
Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):277-82. PubMed ID: 10333200
[TBL] [Abstract][Full Text] [Related]
10. Oral budesonide in active Crohn's disease.
Löfberg R; Danielsson A; Salde L
Aliment Pharmacol Ther; 1993 Dec; 7(6):611-6. PubMed ID: 8161666
[TBL] [Abstract][Full Text] [Related]
11. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
Hanauer S; Sandborn WJ; Persson A; Persson T
Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
[TBL] [Abstract][Full Text] [Related]
12. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.
Spencer CM; McTavish D
Drugs; 1995 Nov; 50(5):854-72. PubMed ID: 8586030
[TBL] [Abstract][Full Text] [Related]
13. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
[TBL] [Abstract][Full Text] [Related]
14. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
15. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
[TBL] [Abstract][Full Text] [Related]
17. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
Escher JC;
Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):47-54. PubMed ID: 15095852
[TBL] [Abstract][Full Text] [Related]
18. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
19. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
[TBL] [Abstract][Full Text] [Related]
20. Budesonide for maintenance of remission in Crohn's disease.
Simms L; Steinhart AH
Cochrane Database Syst Rev; 2001; (1):CD002913. PubMed ID: 11279777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]